

**HIGHLIGHTS OF PRESCRIBING INFORMATION**

These highlights do not include all the information needed to use ALIMTA safely and effectively. See full prescribing information for ALIMTA.

**ALIMTA (pemetrexed for injection) Lyophilized Powder, for Solution for Intravenous Use**

Initial U.S. Approval: 2004

**RECENT MAJOR CHANGES**

Dosage and Administration, Premedication Regimen and Concurrent Medications (2.3)	10/2012
Warnings and Precautions, Requirement for Premedication and Concomitant Medication to Reduce Toxicity (5.1)	10/2012
Warnings and Precautions, Required Laboratory Monitoring (5.5)	10/2012

**INDICATIONS AND USAGE**

ALIMTA<sup>®</sup> is a folate analog metabolic inhibitor indicated for:

- Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer:
  - Initial treatment in combination with cisplatin. (1.1)
  - Maintenance treatment of patients whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. (1.2)
  - After prior chemotherapy as a single-agent. (1.3)
- Mesothelioma: in combination with cisplatin. (1.4)

**Limitations of Use:**

- ALIMTA is not indicated for the treatment of patients with squamous cell non-small cell lung cancer. (1.5)

**DOSAGE AND ADMINISTRATION**

- Combination use in Non-Small Cell Lung Cancer and Mesothelioma: Recommended dose of ALIMTA is 500 mg/m<sup>2</sup> i.v. on Day 1 of each 21-day cycle in combination with cisplatin 75 mg/m<sup>2</sup> i.v. beginning 30 minutes after ALIMTA administration. (2.1)
- Single-Agent use in Non-Small Cell Lung Cancer: Recommended dose of ALIMTA is 500 mg/m<sup>2</sup> i.v. on Day 1 of each 21-day cycle. (2.2)
- Prior to initiating ALIMTA, initiate supplementation with oral folic acid and intramuscular vitamin B<sub>12</sub>. Continue folic acid and vitamin B<sub>12</sub> supplementation throughout treatment. Administer corticosteroids the day before, the day of, and the day after ALIMTA administration. (2.3)
- Dose Reductions: Dose reductions or discontinuation may be needed based on toxicities from the preceding cycle of therapy. (2.4)

**DOSAGE FORMS AND STRENGTHS**

- 100 mg vial for injection (3)
- 500 mg vial for injection (3)

**CONTRAINDICATIONS**

History of severe hypersensitivity reaction to pemetrexed. (4)

**WARNINGS AND PRECAUTIONS**

- Premedication regimen: Prior to treatment with ALIMTA, initiate supplementation with oral folic acid and intramuscular vitamin B<sub>12</sub> to reduce the severity of hematologic and gastrointestinal toxicity of ALIMTA. (5.1)
- Bone marrow suppression: Reduce doses for subsequent cycles based on hematologic and nonhematologic toxicities. (5.2)
- Renal function: Do not administer when CrCl <45 mL/min. (2.4, 5.3)
- NSAIDs with renal insufficiency: Use caution in patients with mild to moderate renal insufficiency (CrCl 45-79 mL/min). (5.4)
- Lab monitoring: Do not initiate a cycle unless ANC ≥1500 cells/mm<sup>3</sup>, platelets ≥100,000 cells/mm<sup>3</sup>, and CrCl ≥45 mL/min. (5.5)
- Pregnancy: Fetal harm can occur when administered to a pregnant woman. Women should be advised to use effective contraception measures to prevent pregnancy during treatment with ALIMTA. (5.6)

**ADVERSE REACTIONS**

The most common adverse reactions (incidence ≥20%) with single-agent use are fatigue, nausea, and anorexia. Additional common adverse reactions when used in combination with cisplatin include vomiting, neutropenia, leukopenia, anemia, stomatitis/pharyngitis, thrombocytopenia, and constipation. (6.1)

**To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

**DRUG INTERACTIONS**

- NSAIDs: Use caution with NSAIDs. (7.1)
- Nephrotoxic drugs: Concomitant use of these drugs and/or substances which are tubularly secreted may result in delayed clearance. (7.2)

**See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.**

Revised: 05/2013

**FULL PRESCRIBING INFORMATION: CONTENTS\*****1 INDICATIONS AND USAGE**

- Nonsquamous Non-Small Cell Lung Cancer – Combination with Cisplatin
- Nonsquamous Non-Small Cell Lung Cancer – Maintenance
- Nonsquamous Non-Small Cell Lung Cancer – After Prior Chemotherapy
- Mesothelioma
- Limitations of Use

**2 DOSAGE AND ADMINISTRATION**

- Combination Use with Cisplatin for Nonsquamous Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma
- Single-Agent Use as Maintenance Following First-Line Therapy, or as a Second-Line Therapy
- Premedication Regimen and Concurrent Medications
- Laboratory Monitoring and Dose Reduction/Discontinuation Recommendations
- Preparation and Administration Precautions
- Preparation for Intravenous Infusion Administration

**4 CONTRAINDICATIONS****5 WARNINGS AND PRECAUTIONS**

- Requirement for Premedication and Concomitant Medication to Reduce Toxicity
- Bone Marrow Suppression
- Decreased Renal Function
- Use with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) with Mild to Moderate Renal Insufficiency
- Required Laboratory Monitoring
- Pregnancy Category D

**6 ADVERSE REACTIONS**

- Clinical Trials Experience
- Postmarketing Experience

**7 DRUG INTERACTIONS**

- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Nephrotoxic Drugs

**8 USE IN SPECIFIC POPULATIONS**

- Pregnancy
- Nursing Mothers

- 8.6 Patients with Hepatic Impairment
- 8.7 Patients with Renal Impairment
- 8.8 Gender
- 8.9 Race
- 10 OVERDOSAGE**
- 11 DESCRIPTION**
- 12 CLINICAL PHARMACOLOGY**
  - 12.1 Mechanism of Action
  - 12.2 Pharmacodynamics
  - 12.3 Pharmacokinetics
- 13 NONCLINICAL TOXICOLOGY**
  - 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

- 14 CLINICAL STUDIES**
  - 14.1 Non-Small Cell Lung Cancer (NSCLC) – Combination with Cisplatin
  - 14.2 Non-Small Cell Lung Cancer – Maintenance
  - 14.3 Non-Small Cell Lung Cancer – After Prior Chemotherapy
  - 14.4 Malignant Pleural Mesothelioma
- 15 REFERENCES**
- 16 HOW SUPPLIED/STORAGE AND HANDLING**
  - 16.1 How Supplied
  - 16.2 Storage and Handling
- 17 PATIENT COUNSELING INFORMATION**

\*Sections or subsections omitted from the full prescribing information are not listed.

## FULL PRESCRIBING INFORMATION

### 1 INDICATIONS AND USAGE

#### 1.1 Nonsquamous Non-Small Cell Lung Cancer – Combination with Cisplatin

ALIMTA<sup>®</sup> is indicated in combination with cisplatin therapy for the initial treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer.

#### 1.2 Nonsquamous Non-Small Cell Lung Cancer – Maintenance

ALIMTA is indicated for the maintenance treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.

#### 1.3 Nonsquamous Non-Small Cell Lung Cancer – After Prior Chemotherapy

ALIMTA is indicated as a single-agent for the treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer after prior chemotherapy.

#### 1.4 Mesothelioma

ALIMTA in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.

#### 1.5 Limitations of Use

ALIMTA is not indicated for the treatment of patients with squamous cell non-small cell lung cancer. [see *Clinical Studies* (14.1, 14.2, 14.3)]

### 2 DOSAGE AND ADMINISTRATION

#### 2.1 Combination Use with Cisplatin for Nonsquamous Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma

The recommended dose of ALIMTA is 500 mg/m<sup>2</sup> administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle. The recommended dose of cisplatin is 75 mg/m<sup>2</sup> infused over 2 hours beginning approximately 30 minutes after the end of ALIMTA administration. See cisplatin package insert for more information.

#### 2.2 Single-Agent Use as Maintenance Following First-Line Therapy, or as a Second-Line Therapy

The recommended dose of ALIMTA is 500 mg/m<sup>2</sup> administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle.

#### 2.3 Premedication Regimen and Concurrent Medications

##### Vitamin Supplementation

Instruct patients to initiate folic acid 400 mcg to 1000 mcg orally once daily beginning 7 days before the first dose of ALIMTA. Continue folic acid during the full course of therapy and for 21 days after the last dose of ALIMTA [see *Warnings and Precautions* (5.1)].

Administer vitamin B<sub>12</sub> 1 mg intramuscularly 1 week prior to the first dose of ALIMTA and every 3 cycles thereafter. Subsequent vitamin B<sub>12</sub> injections may be given the same day as treatment with ALIMTA [see *Warnings and Precautions* (5.1)].

##### Corticosteroids

Administer dexamethasone 4 mg by mouth twice daily the day before, the day of, and the day after ALIMTA administration [see *Warnings and Precautions* (5.1)].

#### 2.4 Laboratory Monitoring and Dose Reduction/Discontinuation Recommendations

##### Monitoring

Complete blood cell counts, including platelet counts, should be performed on all patients receiving ALIMTA. Patients should be monitored for nadir and recovery, which were tested in the clinical study before each dose and on days 8 and 15 of each cycle. Patients should not begin a new cycle of treatment unless the ANC is  $\geq 1500$  cells/mm<sup>3</sup>, the platelet count is  $\geq 100,000$  cells/mm<sup>3</sup>, and creatinine clearance is  $\geq 45$  mL/min. Periodic chemistry tests should be performed to evaluate renal and hepatic function. [see *Warnings and Precautions* (5.1)]

Dose adjustments at the start of a subsequent cycle should be based on nadir hematologic counts or maximum nonhematologic toxicity from the preceding cycle of therapy. Treatment may be delayed to allow sufficient time for recovery. Upon recovery, patients should be retreated using the guidelines in Tables 1-3, which are suitable for using ALIMTA as a single-agent or in combination with cisplatin.

**Table 1: Dose Reduction for ALIMTA (single-agent or in combination) and Cisplatin – Hematologic Toxicities**

Nadir ANC <500/mm <sup>3</sup> and nadir platelets ≥50,000/mm <sup>3</sup> .	75% of previous dose (pemetrexed and cisplatin).
Nadir platelets <50,000/mm <sup>3</sup> without bleeding regardless of nadir ANC.	75% of previous dose (pemetrexed and cisplatin).
Nadir platelets <50,000/mm <sup>3</sup> with bleeding <sup>a</sup> , regardless of nadir ANC.	50% of previous dose (pemetrexed and cisplatin).

<sup>a</sup> These criteria meet the CTC version 2.0 (NCI 1998) definition of ≥CTC Grade 2 bleeding.

If patients develop nonhematologic toxicities (excluding neurotoxicity) ≥Grade 3, treatment should be withheld until resolution to less than or equal to the patient's pre-therapy value. Treatment should be resumed according to guidelines in Table 2.

**Table 2: Dose Reduction for ALIMTA (single-agent or in combination) and Cisplatin – Nonhematologic Toxicities<sup>a,b</sup>**

	Dose of ALIMTA (mg/m <sup>2</sup> )	Dose of Cisplatin (mg/m <sup>2</sup> )
Any Grade 3 or 4 toxicities except mucositis	75% of previous dose	75% of previous dose
Any diarrhea requiring hospitalization (irrespective of Grade) or Grade 3 or 4 diarrhea	75% of previous dose	75% of previous dose
Grade 3 or 4 mucositis	50% of previous dose	100% of previous dose

<sup>a</sup> NCI Common Toxicity Criteria (CTC).

<sup>b</sup> Excluding neurotoxicity (see Table 3).

In the event of neurotoxicity, the recommended dose adjustments for ALIMTA and cisplatin are described in Table 3. Patients should discontinue therapy if Grade 3 or 4 neurotoxicity is experienced.

**Table 3: Dose Reduction for ALIMTA (single-agent or in combination) and Cisplatin – Neurotoxicity**

CTC Grade	Dose of ALIMTA (mg/m <sup>2</sup> )	Dose of Cisplatin (mg/m <sup>2</sup> )
0-1	100% of previous dose	100% of previous dose
2	100% of previous dose	50% of previous dose

#### Discontinuation Recommendation

ALIMTA therapy should be discontinued if a patient experiences any hematologic or nonhematologic Grade 3 or 4 toxicity after 2 dose reductions or immediately if Grade 3 or 4 neurotoxicity is observed.

#### Renally Impaired Patients

In clinical studies, patients with creatinine clearance ≥45 mL/min required no dose adjustments other than those recommended for all patients. Insufficient numbers of patients with creatinine clearance below 45 mL/min have been treated to make dosage recommendations for this group of patients [see *Clinical Pharmacology* (12.3)]. Therefore, ALIMTA should not be administered to patients whose creatinine clearance is <45 mL/min using the standard Cockcroft and Gault formula (below) or GFR measured by Tc99m-DTPA serum clearance method:

$$\begin{aligned} \text{Males:} & \quad \frac{[140 - \text{Age in years}] \times \text{Actual Body Weight (kg)}}{72 \times \text{Serum Creatinine (mg/dL)}} = \text{mL/min} \\ \text{Females:} & \quad \text{Estimated creatinine clearance for males} \times 0.85 \end{aligned}$$

Caution should be exercised when administering ALIMTA concurrently with NSAIDs to patients whose creatinine clearance is <80 mL/min [see *Drug Interactions* (7.1)].

## 2.5 Preparation and Administration Precautions

As with other potentially toxic anticancer agents, care should be exercised in the handling and preparation of infusion solutions of ALIMTA. The use of gloves is recommended. If a solution of ALIMTA contacts the skin, wash the skin immediately and thoroughly with soap and water. If ALIMTA contacts the mucous membranes, flush thoroughly with water. Several published guidelines for handling and disposal of anticancer agents are available [see *References* (15)].

ALIMTA is not a vesicant. There is no specific antidote for extravasation of ALIMTA. To date, there have been few reported cases of ALIMTA extravasation, which were not assessed as serious by the investigator. ALIMTA extravasation should be managed with local standard practice for extravasation as with other non-vesicants.

## 2.6 Preparation for Intravenous Infusion Administration

1. Use aseptic technique during the reconstitution and further dilution of ALIMTA for intravenous infusion administration.
2. Calculate the dose of ALIMTA and determine the number of vials needed. Vials contain either 100 mg or 500 mg of ALIMTA. The vials contain an excess of ALIMTA to facilitate delivery of label amount.
3. Reconstitute each 100-mg vial with 4.2 ml of 0.9% Sodium Chloride Injection (preservative free). Reconstitute each 500-mg vial with 20 mL of 0.9% Sodium Chloride Injection (preservative free). Reconstitution of either size vial gives a solution containing 25 mg/mL ALIMTA. Gently swirl each vial until the powder is completely dissolved. The resulting solution is clear and ranges in color from colorless to yellow or green-yellow without adversely affecting product quality. The pH of the reconstituted ALIMTA solution is between 6.6 and 7.8. FURTHER DILUTION IS REQUIRED.
4. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If particulate matter is observed, do not administer.
5. An appropriate quantity of the reconstituted ALIMTA solution must be further diluted into a solution of 0.9% Sodium Chloride Injection (preservative free), so that the total volume of solution is 100 ml. ALIMTA is administered as an intravenous infusion over 10 minutes.
6. Chemical and physical stability of reconstituted and infusion solutions of ALIMTA were demonstrated for up to 24 hours following initial reconstitution, when stored refrigerated. When prepared as directed, reconstitution and infusion solutions of ALIMTA contain no antimicrobial preservatives. Discard any unused portion.

Reconstitution and further dilution prior to intravenous infusion is only recommended with 0.9% Sodium Chloride Injection (preservative free). ALIMTA is physically incompatible with diluents containing calcium, including Lactated Ringer's Injection, USP and Ringer's Injection, USP and therefore these should not be used. Coadministration of ALIMTA with other drugs and diluents has not been studied, and therefore is not recommended. ALIMTA is compatible with standard polyvinyl chloride (PVC) administration sets and intravenous solution bags.

## 3 DOSAGE FORMS AND STRENGTHS

ALIMTA, pemetrexed for injection, is a white to either light-yellow or green-yellow lyophilized powder available in sterile single-use vials containing 100 mg or 500 mg pemetrexed.

## 4 CONTRAINDICATIONS

ALIMTA is contraindicated in patients who have a history of severe hypersensitivity reaction to pemetrexed.

## 5 WARNINGS AND PRECAUTIONS

### 5.1 Requirement for Premedication and Concomitant Medication to Reduce Toxicity

#### Vitamin Supplementation

Prior to treatment with ALIMTA, initiate supplementation with oral folic acid and intramuscular vitamin B<sub>12</sub> to reduce the severity of hematologic and gastrointestinal toxicity of ALIMTA [see *Dosage and Administration* (2.3)]. Do not substitute oral vitamin B<sub>12</sub> for intramuscular vitamin B<sub>12</sub>. In clinical studies, the incidence of the following Grade 3-4 toxicities were higher in patients with mesothelioma who were never supplemented as compared to patients who were fully supplemented with folic acid and vitamin B<sub>12</sub> prior to and throughout ALIMTA treatment: neutropenia [38% versus 23%], thrombocytopenia [9% versus 5%], febrile neutropenia [9% versus 0.6%], and infection with neutropenia [6% versus 0].

#### Corticosteroids

Administer dexamethasone the day before, the day of, and the day after ALIMTA administration [see *Dosage and Administration* (2.3)].

### 5.2 Bone Marrow Suppression

ALIMTA can suppress bone marrow function, as manifested by neutropenia, thrombocytopenia, and anemia (or pancytopenia) [see *Adverse Reactions* (6.1)]; myelosuppression is usually the dose-limiting toxicity. Dose reductions for subsequent cycles are based on nadir ANC, platelet count, and maximum nonhematologic toxicity seen in the previous cycle [see *Dosage and Administration* (2.4)].

### 5.3 Decreased Renal Function

ALIMTA is primarily eliminated unchanged by renal excretion. No dosage adjustment is needed in patients with creatinine clearance  $\geq 45$  mL/min. Insufficient numbers of patients have been studied with creatinine clearance  $< 45$  mL/min to give a dose recommendation. Therefore, ALIMTA should not be administered to patients whose creatinine clearance is  $< 45$  mL/min [see *Dosage and Administration* (2.4)].

One patient with severe renal impairment (creatinine clearance 19 mL/min) who did not receive folic acid and vitamin B<sub>12</sub> died of drug-related toxicity following administration of ALIMTA alone.

Caution should be used when administering NSAIDs concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min) [see *Drug Interactions (7.1)*].

### 5.5 Required Laboratory Monitoring

Obtain a complete blood count and renal function tests at the beginning of each cycle and as needed. Do not initiate a cycle of treatment unless the ANC is  $\geq 1500$  cells/mm<sup>3</sup>, the platelet count is  $\geq 100,000$  cells/mm<sup>3</sup>, and creatinine clearance is  $\geq 45$  mL/min [see *Dosage and Administration (2.4)*].

### 5.6 Pregnancy Category D

Based on its mechanism of action, ALIMTA can cause fetal harm when administered to a pregnant woman. Pemetrexed administered intraperitoneally to mice during organogenesis was embryotoxic, fetotoxic and teratogenic in mice at greater than 1/833rd the recommended human dose. If ALIMTA is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant. Women should be advised to use effective contraceptive measures to prevent pregnancy during treatment with ALIMTA [see *Use in Specific Populations (8.1)*].

## 6 ADVERSE REACTIONS

### 6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reactions rates cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.

In clinical trials, the most common adverse reactions (incidence  $\geq 20\%$ ) during therapy with ALIMTA as a single-agent were fatigue, nausea, and anorexia. Additional common adverse reactions (incidence  $\geq 20\%$ ) during therapy with ALIMTA when used in combination with cisplatin included vomiting, neutropenia, leukopenia, anemia, stomatitis/pharyngitis, thrombocytopenia, and constipation.

#### Non-Small Cell Lung Cancer (NSCLC) – ALIMTA in Combination with Cisplatin

Table 4 provides the frequency and severity of adverse reactions that have been reported in  $>5\%$  of 839 patients with NSCLC who were randomized to study and received ALIMTA plus cisplatin and 830 patients with NSCLC who were randomized to study and received gemcitabine plus cisplatin. All patients received study therapy as initial treatment for locally advanced or metastatic NSCLC and patients in both treatment groups were fully supplemented with folic acid and vitamin B<sub>12</sub>.

**Table 4: Adverse Reactions in Fully Supplemented Patients Receiving ALIMTA plus Cisplatin in NSCLC<sup>a</sup>**

Reaction <sup>b</sup>	ALIMTA/cisplatin (N=839)		Gemcitabine/cisplatin (N=830)	
	All Grades Toxicity (%)	Grade 3-4 Toxicity (%)	All Grades Toxicity (%)	Grade 3-4 Toxicity (%)
<b>All Adverse Reactions</b>	90	37	91	53
<b>Laboratory</b>				
<b>Hematologic</b>				
Anemia	33	6	46	10
Neutropenia	29	15	38	27
Leukopenia	18	5	21	8
Thrombocytopenia	10	4	27	13
<b>Renal</b>				
Creatinine elevation	10	1	7	1
<b>Clinical</b>				
<b>Constitutional Symptoms</b>				
Fatigue	43	7	45	5
<b>Gastrointestinal</b>				
Nausea	56	7	53	4
Vomiting	40	6	36	6
Anorexia	27	2	24	1
Constipation	21	1	20	0
Stomatitis/Pharyngitis	14	1	12	0
Diarrhea	12	1	13	2
Dyspepsia/Heartburn	5	0	6	0
<b>Neurology</b>				
Neuropathy-sensory	9	0	12	1
Taste disturbance	8	0 <sup>c</sup>	9	0 <sup>c</sup>
<b>Dermatology/Skin</b>				



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.